A $25 Million 'Cautionary Tale': CIRM and Geron
California's $25 million venture into the financing of what once was the first hESC clinical trial in the nation serves as a "cautionary tale" for states that use taxpayer dollars to boost technology, according to a New York public policy expert.
The comments by James W. Fossett, who directs the Rockefeller Institute of Government health, Medicaid studie…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.